Humira (adalimumab) and Remicade (infliximab) are prescription drugs used to treat certain inflammatory conditions. Humira is given as an injection, while Remicade is given as an infusion. Humira and ...

The biosimilar Hyrimoz showed similar flare rates to Humira, but 25% of patients experienced adverse events, mainly injection site reactions. Injection pain, linked to Hyrimoz's citrate content and ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Patients in early rheumatoid arthritis respond well to either abatacept or adalimumab, with the ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Among adults treated with adalimumab, those with hidradenitis suppurativa (HS) showed a 53% higher risk for serious infections than adults with psoriasis, with notably increased risks for sepsis and ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but their relative effects on pain, versus inflammation, are less ...

Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...